149 related articles for article (PubMed ID: 18035525)
1. Evaluation of in vitro in vivo correlations for dry powder inhaler delivery using artificial neural networks.
de Matas M; Shao Q; Richardson CH; Chrystyn H
Eur J Pharm Sci; 2008 Jan; 33(1):80-90. PubMed ID: 18035525
[TBL] [Abstract][Full Text] [Related]
2. The relative bioavailability of salbutamol to the lung using urinary excretion following inhalation from a novel dry powder inhaler: the effect of inhalation rate and formulation.
Chege JK; Chrystyn H
Respir Med; 2000 Jan; 94(1):51-6. PubMed ID: 10714479
[TBL] [Abstract][Full Text] [Related]
3. Comparison of bronchodilating effects of two salbutamol dry powder inhalers in asthmatic patients.
Laurikainen K; Silvasti M; Calderon P; Lins R; Rosillon D
Arzneimittelforschung; 1997 Jan; 47(1):44-6. PubMed ID: 9037443
[TBL] [Abstract][Full Text] [Related]
4. [Comparison of the bronchodilator effect of salbutamol between pressure metered dosed inhaler and dry powder inhaler in patients with stable bronchial asthma].
Yoshimi Y; Fujimura M; Yasui M; Kasahara K; Nakao S
Arerugi; 2004 May; 53(5):502-7. PubMed ID: 15247530
[TBL] [Abstract][Full Text] [Related]
5. Do all dry powder inhalers show the same pharmaceutical performance?
Taylor A; Gustafsson P
Int J Clin Pract Suppl; 2005 Dec; (149):7-12. PubMed ID: 16279997
[TBL] [Abstract][Full Text] [Related]
6. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
Zeng XM; MacRitchie HB; Marriott C; Martin GP
Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
[TBL] [Abstract][Full Text] [Related]
7. Lung delivery of salbutamol given by breath activated pressurized aerosol and dry powder inhaler devices.
Lipworth BJ; Clark DJ
Pulm Pharmacol Ther; 1997 Aug; 10(4):211-4. PubMed ID: 9695144
[TBL] [Abstract][Full Text] [Related]
8. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246
[TBL] [Abstract][Full Text] [Related]
9. The study of in vitro-in vivo correlation: pharmacokinetics and pharmacodynamics of albuterol dry powder inhalers.
Srichana T; Suedee R; Muanpanarai D; Tanmanee N
J Pharm Sci; 2005 Jan; 94(1):220-30. PubMed ID: 15761945
[TBL] [Abstract][Full Text] [Related]
10. The correlation of urinary levels of albuterol and its metabolites isomers following inhalation from a dry powder inhaler and in vitro particle size characterisation.
Srichana T; Suedee R; Tanmanee N; Muanpanarai D; Marriott C
Pulm Pharmacol Ther; 2007; 20(1):36-45. PubMed ID: 16325440
[TBL] [Abstract][Full Text] [Related]
11. Variability of fine particle dose and lung deposition of budesonide delivered through two multidose dry powder inhalers.
Munzel U; Marschall K; Fyrnys B; Wedel M
Curr Med Res Opin; 2005 Jun; 21(6):827-33. PubMed ID: 15969882
[TBL] [Abstract][Full Text] [Related]
12. In-vitro characterisation of metered dose inhaler versus dry powder inhaler glucocorticoid products: influence of inspiratory flow rates.
Feddah MR; Brown KF; Gipps EM; Davies NM
J Pharm Pharm Sci; 2000; 3(3):318-24. PubMed ID: 11177650
[TBL] [Abstract][Full Text] [Related]
13. Can patients use all dry powder inhalers equally well?
Gustafsson P; Taylor A; Zanen P; Chrystyn H
Int J Clin Pract Suppl; 2005 Dec; (149):13-8. PubMed ID: 16279998
[TBL] [Abstract][Full Text] [Related]
14. Concurrent use of metered-dose and dry powder inhalers by children with persistent asthma does not adversely affect spacer/inhaler technique.
Chan DS; Callahan CW; Hatch-Pigott VB; Lawless A; Proffitt HL; Manning NE; Schweikert MP
Ann Pharmacother; 2006 Oct; 40(10):1743-6. PubMed ID: 16968822
[TBL] [Abstract][Full Text] [Related]
15. Effects of airway calibre on lung delivery of nebulised salbutamol.
Lipworth BJ; Clark DJ
Thorax; 1997 Dec; 52(12):1036-9. PubMed ID: 9516895
[TBL] [Abstract][Full Text] [Related]
16. Reproducibility of bronchodilator response for a reservoir dry powder inhaler following routine clinical use.
Morice AH; Peake MD; Allen MB; Campbell JC; Parry-Billings M
J Asthma; 2000 Feb; 37(1):81-7. PubMed ID: 10724301
[TBL] [Abstract][Full Text] [Related]
17. Relative bioavailability of salbutamol to the lung following inhalation via a novel dry powder inhaler and a standard metered dose inhaler.
Hindle M; Peers EM; Parry-Billings M; Chrystyn H
Br J Clin Pharmacol; 1997 Mar; 43(3):336-8. PubMed ID: 9088593
[TBL] [Abstract][Full Text] [Related]
18. Pharmacoscintigraphic evaluation of lipid dry powder budesonide formulations for inhalation.
Sebti T; Pilcer G; Van Gansbeke B; Goldman S; Michils A; Vanderbist F; Amighi K
Eur J Pharm Biopharm; 2006 Aug; 64(1):26-32. PubMed ID: 16697169
[TBL] [Abstract][Full Text] [Related]
19. Highly reproducible powder aerosolisation for lung delivery using powder-specific electromechanical vibration.
Crowder TM
Expert Opin Drug Deliv; 2005 May; 2(3):579-85. PubMed ID: 16296776
[TBL] [Abstract][Full Text] [Related]
20. Determination of the relative bioavailability of salbutamol to the lungs and systemic circulation following nebulization.
Silkstone VL; Corlett SA; Chrystyn H
Br J Clin Pharmacol; 2002 Aug; 54(2):115-9. PubMed ID: 12207629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
